A-METHAPRED (methylprednisolone sodium succinate)
TRICHINOSIS·+52
HOSPIRA
Indication
Progressive diffuse large B-cell lymphoma
Progressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy. Read more about Progressive diffuse large B-cell lymphoma
147 drugs 98 manufacturers
Drugs that treat it
Common Progressive diffuse large B-cell lymphoma therapies.
DEXAMETHASONE SODIUM PHOSPHATE (dexamethasone sodium phosphate/PF)
DISSEMINATED TUBERCULOSIS·+60
APP PHARMACEUTI
DEXPAK (dexamethasone)
DISSEMINATED TUBERCULOSIS·+61
ECR PHARM.
DEXPAK (dexamethasone)
DISSEMINATED TUBERCULOSIS·+61
ECR PHARM.
SOLU-MEDROL (methylprednisolone sodium succinate/PF)
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+52
Laboratories Div
DEXAMETHASONE
GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+61
RISING PHARM
DEXAMETHASONE SODIUM PHOSPHATE
DISSEMINATED TUBERCULOSIS·+60
WEST-WARD,INC.
DEXAMETHASONE SODIUM PHOSPHATE
DISSEMINATED TUBERCULOSIS·+60
APP PHARMACEUTI
DEXPAK (dexamethasone)
DISSEMINATED TUBERCULOSIS·+61
ECR PHARM.
Filter & compare in the drug finder →Opens the drug finder with Progressive diffuse large B-cell lymphoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonProgressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy.
Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), and systemic constitutional B symptoms.
Pathophysiologically, it is defined by the proliferation of large, atypical neoplastic B cells that disrupt normal tissue architecture and evade standard therapeutic suppression, reflecting refractory clonal expansion or treatment resistance.
- cancer.gov
Progressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), a...
- nih.gov
Progressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), a...
- lymphoma.org
Progressive diffuse large B-cell lymphoma (DLBCL) describes an aggressive, fast-growing non-Hodgkin lymphoma that exhibits active disease advancement, increasing tumor burden, or the emergence of new malignant lesions during or following therapy Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), a...
- mayoclinic.org
Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), and systemic constitutional B symptoms Pathophysiologically, it is defined by the proliferation of large, atypical neoplastic B cells that disrupt normal tissue architecture and evade standard therapeutic suppression, reflecting refractory clonal ...
- sobi.com
Arising from mature B lymphocytes within the lymphatic system, this clinical state most commonly affects adults and presents as enlarging lymphadenopathy, extranodal organ involvement (such as the gastrointestinal tract, liver, spleen, or bone marrow), and systemic constitutional B symptoms
Personalize your experience
Follow Progressive diffuse large B-cell lymphoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.